Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient.
Esteve
Maria
M
Loras
Carme
C
González-Huix
Ferran
F
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000032:analysis* / Q000627:therapeutic use; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy*; D004351:Drug Resistance; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D000069285:Infliximab; D019259:Lamivudine; D008297:Male; D017410:Practice Guidelines as Topic; D014775:Virus Activation
D000911:Antibodies, Monoclonal; D019259:Lamivudine; D000069285:Infliximab